HEPT

Cat. No.: HY-10892: Data Sheet Handling Instructions
FAQs
Technical Support

HEPT is a potent and selective anti-HIV-1 agent.

For research use only. We do not sell to patients.

HEPT Chemical Structure

CAS No. : 123027-56-5

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

Biological Activity
Purity & Documentation
References
Customer Review

Description

HEPT is a potent and selective anti-HIV-1 agent^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	400 3 Compound: HEPT	Cytotoxic concentration for inhibition of HTLB-IIIB replication in CEM cells. Cytotoxic concentration for inhibition of HTLB-IIIB replication in CEM cells.	[PMID: 9240351]
CCRF-CEM	CC₅₀	> 1 3 Compound: HEPT	Concentration which reduces the cell viability by 50% (CEM-SS / MT-4) Concentration which reduces the cell viability by 50% (CEM-SS / MT-4)	[PMID: 9191961]
CCRF-CEM	CC₅₀	>1 3 Compound: HEPT	Concentration which reduces the cell viability by 50% (CEM-SS / MT-4) Concentration which reduces the cell viability by 50% (CEM-SS / MT-4)	[PMID: 9191961]
CCRF-CEM	CC₅₀	400 3 Compound: HEPT	Cytotoxic concentration for inhibition of HTLB-IIIB replication in CEM cells. Cytotoxic concentration for inhibition of HTLB-IIIB replication in CEM cells.	[PMID: 9240351]
MT4	CC₅₀	> 200 6 Compound: HEPT	Concentration required to reduce human MT-4 cell viability by 50%. Concentration required to reduce human MT-4 cell viability by 50%.	[PMID: 1495006]
CCRF-CEM	CC₅₀	> 1 3 Compound: HEPT	Concentration which reduces the cell viability by 50% (CEM-SS / MT-4) Concentration which reduces the cell viability by 50% (CEM-SS / MT-4)	[PMID: 9191961]
CCRF-CEM	EC₅₀	8.3 3 Compound: HEPT	Effective concentration for inhibition of HTLB-IIIB replication in CEM cells. Effective concentration for inhibition of HTLB-IIIB replication in CEM cells.	[PMID: 9240351]
CCRF-CEM	EC₅₀	8.3 3 Compound: HEPT	Effective concentration for inhibition of HTLB-IIIB replication in CEM cells. Effective concentration for inhibition of HTLB-IIIB replication in CEM cells.	[PMID: 9240351]
MT4	CC₅₀	> 25 6 Compound: HEPT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22652226]
CCRF-CEM	EC₅₀	> 100 3 Compound: 5 (HEPT)	Inhibitory effect against HIV-2 replication in CEM /TK-(thymidine kinase deficient) cells. Inhibitory effect against HIV-2 replication in CEM /TK-(thymidine kinase deficient) cells.	[PMID: 7538589]
CCRF-CEM	EC₅₀	>100 3 Compound: 5 (HEPT)	Inhibitory effect against HIV-2 replication in CEM /TK-(thymidine kinase deficient) cells. Inhibitory effect against HIV-2 replication in CEM /TK-(thymidine kinase deficient) cells.	[PMID: 7538589]
MT4	IC₅₀	> 405.38 3 Compound: HEPT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 18692274]
CCRF-CEM	EC₅₀	> 100 3 Compound: 5 (HEPT)	Inhibitory effect against HIV-2 replication in CEM cells. Inhibitory effect against HIV-2 replication in CEM cells.	[PMID: 7538589]
CEM-SS	IC₅₀	2 3 Compound: HEPT	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line CEM-SS/LAI Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line CEM-SS/LAI	[PMID: 9191961]
MT4	IC₅₀	> 405.8 3 Compound: 1, HEPT	Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method	[PMID: 17095124]
Lymphocyte	EC₅₀	5.5 6 Compound: HEPT	Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells. Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells.	[PMID: 1495006]
MT4	CC₅₀	> 500 3 Compound: 1	Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50% Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50%	[PMID: 2016729]
CEM-SS	IC₅₀	2 3 Compound: HEPT	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line CEM-SS/LAI Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line CEM-SS/LAI	[PMID: 9191961]
Lymphocyte	EC₅₀	5.5 6 Compound: HEPT	Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells. Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells.	[PMID: 1495006]
MT4	CC₅₀	>500 3 Compound: 1	Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50% Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50%	[PMID: 2016729]
MT4	CC₅₀	> 500 3 Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells (HIV-1 HTLV-IIIB strain) by 50% was determined on 4th day after virus infection. Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells (HIV-1 HTLV-IIIB strain) by 50% was determined on 4th day after virus infection.	[PMID: 1992136]
MT4	CC₅₀	405 3 Compound: 1, HEPT	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	CC₅₀	740 3 Compound: HEPT	Concentration of compound required to reduce the viability of mock-infected HIV-2 (LAV-2ROD)/MT-4 cells by 50% Concentration of compound required to reduce the viability of mock-infected HIV-2 (LAV-2ROD)/MT-4 cells by 50%	[PMID: 1732552]
MT4	CC₅₀	≤ 399 3 Compound: HEPT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18692274]
MT4	CC₅₀	405 3 Compound: HEPT	Cytotoxic concentration that reduces the MT-4 cell viability by 50% Cytotoxic concentration that reduces the MT-4 cell viability by 50%	[PMID: 15149669]
MT4	CC₅₀	>200 6 Compound: HEPT	Concentration required to reduce human MT-4 cell viability by 50%. Concentration required to reduce human MT-4 cell viability by 50%.	[PMID: 1495006]
MT4	EC₅₀	3.28 3 Compound: HEPT	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	[PMID: 22652226]
MT4	CC₅₀	743 3 Compound: HEPT	Concentration required to reduce the viability of mock-infected MT-4 cells by 50%. Concentration required to reduce the viability of mock-infected MT-4 cells by 50%.	[PMID: 1732552]
MT4	CC₅₀	405 3 Compound: HEPT	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17381078]
MT4	CC₅₀	405 3 Compound: HEPT	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17381078]
MT4	CC₅₀	405 3 Compound: 1, HEPT	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	CC₅₀	740 3 Compound: 1	Concentration required to reduce viability of mock-infected MT-4 cells Concentration required to reduce viability of mock-infected MT-4 cells	[PMID: 1469700]
MT4	CC₅₀	740 3 Compound: 1	Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells by 50%	10.1016/S0960-894X(00)80042-6
MT4	CC₅₀	740 3 Compound: 1	Concentration required to reduce viability of mock-infected MT-4 cells Concentration required to reduce viability of mock-infected MT-4 cells	[PMID: 1469700]
MT4	CC₅₀	405 3 Compound: HEPT	Cytotoxic concentration that reduces the MT-4 cell viability by 50% Cytotoxic concentration that reduces the MT-4 cell viability by 50%	[PMID: 15149669]
MT4	CC₅₀	740 3 Compound: HEPT	Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells against the HIV-1 (HTLV-IIIB)induced cytopathic effect Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells against the HIV-1 (HTLV-IIIB)induced cytopathic effect	[PMID: 2016715]
MT4	CC₅₀	740 3 Compound: 5e	Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 2479745]
MT4	IC₅₀	5.06 3 Compound: HEPT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 18692274]
MT4	CC₅₀	740 3 Compound: 1; HEPT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability Cytotoxicity against human MT4 cells assessed as reduction in cell viability	[PMID: 36442370]
MT4	CC₅₀	740 3 Compound: 5e	Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 2479745]
MT4	IC₅₀	5.06 3 Compound: HEPT	Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method	[PMID: 17381078]
MT4	CC₅₀	>500 3 Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells (HIV-1 HTLV-IIIB strain) by 50% was determined on 4th day after virus infection. Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells (HIV-1 HTLV-IIIB strain) by 50% was determined on 4th day after virus infection.	[PMID: 1992136]
MT4	CC₅₀	740 3 Compound: HEPT	Concentration of compound required to reduce the viability of mock-infected HIV-2 (LAV-2ROD)/MT-4 cells by 50% Concentration of compound required to reduce the viability of mock-infected HIV-2 (LAV-2ROD)/MT-4 cells by 50%	[PMID: 1732552]
MT4	IC₅₀	5.06 3 Compound: 1, HEPT	Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	CC₅₀	740 3 Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 1992136]
MT4	CC₅₀	740 3 Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 7636846]
MT4	IC₅₀	5.06 3 Compound: HEPT	Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells	[PMID: 15149669]
MT4	CC₅₀	740 3 Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 1992136]
MT4	CC₅₀	740 3 Compound: HEPT	Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells against the HIV-1 (HTLV-IIIB)induced cytopathic effect Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells against the HIV-1 (HTLV-IIIB)induced cytopathic effect	[PMID: 2016715]
MT4	CC₅₀	740 3 Compound: 1	Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells by 50%	10.1016/S0960-894X(00)80042-6
MT4	CC₅₀	740 3 Compound: 1	Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells by 50%	10.1016/S0960-894X(00)80042-6
MT4	CC₅₀	740 3 Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 7636846]
MT4	CC₅₀	740 3 Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 7636846]
MT4	CC₅₀	405 3 Compound: HEPT	Cytotoxic concentration that reduces the MT-4 cell viability by 50% Cytotoxic concentration that reduces the MT-4 cell viability by 50%	[PMID: 15149669]
MT4	CC₅₀	743 3 Compound: HEPT	Concentration required to reduce the viability of mock-infected MT-4 cells by 50%. Concentration required to reduce the viability of mock-infected MT-4 cells by 50%.	[PMID: 1732552]
MT4	CC₅₀	>25 6 Compound: HEPT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22652226]
MT4	CC₅₀	740 3 Compound: 5e	Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 2479745]
MT4	CC₅₀	<= 399 3 Compound: HEPT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18692274]
MT4	CC₅₀	740 3 Compound: 1; HEPT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability Cytotoxicity against human MT4 cells assessed as reduction in cell viability	[PMID: 36442370]
MT4	CC₅₀	740 3 Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 1992136]
MT4	CC₅₀	> 200 6 Compound: HEPT	Concentration required to reduce human MT-4 cell viability by 50%. Concentration required to reduce human MT-4 cell viability by 50%.	[PMID: 1495006]
MT4	CC₅₀	<= 399 3 Compound: HEPT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18692274]
MT4	CC₅₀	740 3 Compound: HEPT	Concentration of compound required to reduce the viability of mock-infected HIV-2 (LAV-2ROD)/MT-4 cells by 50% Concentration of compound required to reduce the viability of mock-infected HIV-2 (LAV-2ROD)/MT-4 cells by 50%	[PMID: 1732552]
MT4	CC₅₀	743 3 Compound: HEPT	Concentration required to reduce the viability of mock-infected MT-4 cells by 50%. Concentration required to reduce the viability of mock-infected MT-4 cells by 50%.	[PMID: 1732552]
MT4	CC₅₀	> 25 6 Compound: HEPT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22652226]
MT4	CC₅₀	405 3 Compound: 1, HEPT	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	CC₅₀	> 500 3 Compound: 1	Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50% Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50%	[PMID: 2016729]
MT4	CC₅₀	405 3 Compound: HEPT	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17381078]
MT4	CC₅₀	> 500 3 Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells (HIV-1 HTLV-IIIB strain) by 50% was determined on 4th day after virus infection. Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells (HIV-1 HTLV-IIIB strain) by 50% was determined on 4th day after virus infection.	[PMID: 1992136]
MT4	EC₅₀	3.28 3 Compound: HEPT	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	[PMID: 22652226]
MT4	EC₅₀	3.28 3 Compound: HEPT	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	[PMID: 22652226]
MT4	EC₅₀	6.5 3 Compound: HEPT	Compound was evaluated for effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 Compound was evaluated for effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1	[PMID: 7540209]
MT4	EC₅₀	6.5 3 Compound: 1	Concentration of compound required to achieve 50% protection of MT-4 cells against HIV-1 virus induced cytopathic effect Concentration of compound required to achieve 50% protection of MT-4 cells against HIV-1 virus induced cytopathic effect	[PMID: 2016729]
MT4	EC₅₀	6.5 3 Compound: 1	Concentration of compound required to achieve 50% protection of MT-4 cells against HIV-1 virus induced cytopathic effect Concentration of compound required to achieve 50% protection of MT-4 cells against HIV-1 virus induced cytopathic effect	[PMID: 2016729]
MT4	EC₅₀	6.5 3 Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB strain) and determined on 4th day after virus infection. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB strain) and determined on 4th day after virus infection.	[PMID: 1992136]
MT4	EC₅₀	>250 3 Compound: HEPT	Concentration required inhibit HIV-2 (LAV-2ROD)replication in MT-4 cells. Concentration required inhibit HIV-2 (LAV-2ROD)replication in MT-4 cells.	[PMID: 1732552]
MT4	EC₅₀	7 3 Compound: 5e	Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1	[PMID: 2479745]
MT4	EC₅₀	6.5 3 Compound: HEPT	Compound was evaluated for effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 Compound was evaluated for effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1	[PMID: 7540209]
MT4	EC₅₀	7 3 Compound: 1	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1	10.1016/S0960-894X(00)80042-6
MT4	EC₅₀	7 3 Compound: HEPT	Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1. Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1.	[PMID: 1732552]
MT4	EC₅₀	7 3 Compound: 1	Effective concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1 Effective concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1	[PMID: 1469700]
MT4	EC₅₀	7 3 Compound: 1	Effective concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1 Effective concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1	[PMID: 1469700]
MT4	EC₅₀	7 3 Compound: 5e	Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1	[PMID: 2479745]
MT4	EC₅₀	7 3 Compound: 1	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1	10.1016/S0960-894X(00)80042-6
MT4	EC₅₀	7 3 Compound: HEPT	Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1. Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1.	[PMID: 1732552]
MT4	EC₅₀	6.5 3 Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB strain) and determined on 4th day after virus infection. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB strain) and determined on 4th day after virus infection.	[PMID: 1992136]
MT4	EC₅₀	7 3 Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB). Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB).	[PMID: 1992136]
MT4	EC₅₀	7 3 Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB). Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB).	[PMID: 1992136]
MT4	EC₅₀	7 3 Compound: HEPT	Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in MT-4 cells Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in MT-4 cells	[PMID: 2016715]
MT4	EC₅₀	8.1 3 Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIRF strain) and determined on 4th day after virus infection. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIRF strain) and determined on 4th day after virus infection.	[PMID: 1992136]
MT4	EC₅₀	7 3 Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus.	[PMID: 7636846]
MT4	EC₅₀	7 3 Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus.	[PMID: 7636846]
MT4	EC₅₀	8.1 3 Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIRF strain) and determined on 4th day after virus infection. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIRF strain) and determined on 4th day after virus infection.	[PMID: 1992136]
MT4	EC₅₀	>250 3 Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 ((LAV-2EHO strain) and determined on 4th day after virus infection. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 ((LAV-2EHO strain) and determined on 4th day after virus infection.	[PMID: 1992136]
MT4	EC₅₀	8.1 3 Compound: HEPT	Inhibitory activity against HIV-1 (HTLV-IIIRF strain) replication in MT-4 cells Inhibitory activity against HIV-1 (HTLV-IIIRF strain) replication in MT-4 cells	[PMID: 2016715]
MT4	EC₅₀	7 3 Compound: HEPT	Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in MT-4 cells Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in MT-4 cells	[PMID: 2016715]
MT4	EC₅₀	> 250 3 Compound: HEPT	Concentration required inhibit HIV-2 (LAV-2ROD)replication in MT-4 cells. Concentration required inhibit HIV-2 (LAV-2ROD)replication in MT-4 cells.	[PMID: 1732552]
MT4	EC₅₀	8.1 3 Compound: HEPT	Inhibitory activity against HIV-1 (HTLV-IIIRF strain) replication in MT-4 cells Inhibitory activity against HIV-1 (HTLV-IIIRF strain) replication in MT-4 cells	[PMID: 2016715]
MT4	EC₅₀	> 250 3 Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 ((LAV-2EHO strain) and determined on 4th day after virus infection. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 ((LAV-2EHO strain) and determined on 4th day after virus infection.	[PMID: 1992136]
MT4	EC₅₀	>250 3 Compound: HEPT	Inhibitory activity against HIV-2(LAV-2EHO strain) replication in MT-4 cells Inhibitory activity against HIV-2(LAV-2EHO strain) replication in MT-4 cells	[PMID: 2016715]
MT4	EC₅₀	> 250 3 Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 (LAV-2ROD strain) and determined on 4th day after virus infection. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 (LAV-2ROD strain) and determined on 4th day after virus infection.	[PMID: 1992136]
MT4	IC₅₀	5.06 3 Compound: 1, HEPT	Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	EC₅₀	> 250 3 Compound: HEPT	Inhibitory activity against HIV-2(LAV-2EHO strain) replication in MT-4 cells Inhibitory activity against HIV-2(LAV-2EHO strain) replication in MT-4 cells	[PMID: 2016715]
MT4	IC₅₀	5.06 3 Compound: HEPT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 18692274]
MT4	EC₅₀	> 250 3 Compound: HEPT	Inhibitory activity against HIV-2(LAV-2ROD strain) replication in MT-4 cells Inhibitory activity against HIV-2(LAV-2ROD strain) replication in MT-4 cells	[PMID: 2016715]
MT4	IC₅₀	5.15 3 Compound: 35	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from cytopathic effect Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from cytopathic effect	[PMID: 24657566]
MT4	IC₅₀	>405.8 3 Compound: 1, HEPT	Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	IC₅₀	11 3 Compound: HEPT	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line MT-4 IIIB Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line MT-4 IIIB	[PMID: 9191961]
MT4	IC₅₀	5.06 3 Compound: 1, HEPT	Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	IC₅₀	>405.38 3 Compound: HEPT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 18692274]
MT4	IC₅₀	5.06 3 Compound: HEPT	Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells	[PMID: 15149669]
MT4	IC₅₀	5.06 3 Compound: HEPT	Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method	[PMID: 17381078]
MT4	IC₅₀	5.06 3 Compound: HEPT	Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method	[PMID: 17381078]
MT4	IC₅₀	5.06 3 Compound: HEPT	Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells	[PMID: 15149669]
MT4	IC₅₀	11 3 Compound: HEPT	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line MT-4 IIIB Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line MT-4 IIIB	[PMID: 9191961]
MT4	IC₅₀	5.06 3 Compound: HEPT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 18692274]
MT4	IC₅₀	5.15 3 Compound: 35	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from cytopathic effect Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from cytopathic effect	[PMID: 24657566]
MT4	IC₅₀	>405 3 Compound: HEPT	Inhibitory concentration against SO561945 (HIV 1 mutant RT) viral infection of MT-4 cells Inhibitory concentration against SO561945 (HIV 1 mutant RT) viral infection of MT-4 cells	[PMID: 15149669]
Vero	EC₅₀	>100 3 Compound: 1	Antiviral activity against Vero cells, infected with HSV-1. Antiviral activity against Vero cells, infected with HSV-1.	[PMID: 1720175]
MT4	IC₅₀	> 405 3 Compound: HEPT	Inhibitory concentration against SO561945 (HIV 1 mutant RT) viral infection of MT-4 cells Inhibitory concentration against SO561945 (HIV 1 mutant RT) viral infection of MT-4 cells	[PMID: 15149669]
MT4	IC₅₀	> 405.38 3 Compound: HEPT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 18692274]
Vero	IC₅₀	>100 3 Compound: 1	The compound was tested for toxicity in Vero cells. The compound was tested for toxicity in Vero cells.	[PMID: 1720175]
MT4	IC₅₀	> 405.8 3 Compound: 1, HEPT	Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method	[PMID: 17095124]
Vero	EC₅₀	> 100 3 Compound: 1	Antiviral activity against Vero cells, infected with HSV-1. Antiviral activity against Vero cells, infected with HSV-1.	[PMID: 1720175]
Vero	IC₅₀	> 100 3 Compound: 1	The compound was tested for toxicity in Vero cells. The compound was tested for toxicity in Vero cells.	[PMID: 1720175]

Molecular Weight

308.35

Formula

C₁₄H₁₆N₂O₄S

CAS No.

123027-56-5

SMILES

O=C1NC(C(C)=C(SC2=CC=CC=C2)N1COCCO)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Tanaka H, et al. A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). J Med Chem. 1991 Jan;34(1):349-57. [Content Brief]

HEPT Related Classifications

Infection

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

HEPT123027-56-5HIVHuman immunodeficiency virusanti-HIV-1 agentInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

HEPT

HEPT Related Antibodies

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

HEPT Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report